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What is epratuzumab and why is it important?
Of all the candidate biologic drugs for autoimmune disorders that have been studied over the last 20 years, epratuzumab is one of the most interesting. CD22 is a 135-kd, type 1, transmembrane sialoglycoprotein of the immunoglobulin superfamily. It modulates signaling via the B cell antigen receptor complex, regulating B cell activation and survival (1) . Epratuzumab was first used in animal models in 2001. A humanized (complementarity-determining regions-grafted) anti-CD22 monoclonal antibody reacting with the third immunoglobulin-like domain of CD22, it is an immunomodulating agent (unlike its cytotoxic cousin, rituximab), and leads to a reduction in B cell activity and the number of B cells in peripheral blood (by~30%). As an inhibitory co-receptor of the B cell receptor (BCR), epratuzumab leads to its internalization and phosphorylation, resulting in removal of the BCR from the cell surface, down-modulating BCR-activated signaling, and ultimately reducing maturation and proliferation of B cells and adhesion molecules, and decreasing production of proinflammatory cytokines (particularly interleukin-6 and TNF).
Numerous studies since 2003 have demonstrated the effectiveness of epratuzumab in treating non-Hodgkin's lymphoma and acute lymphocytic leukemias in combination with other therapies (1). However, along the way epratuzumab was noted to exhibit additional immunomodulating activity in autoimmunity, which led some investigators to call it the "hydroxychloroquine of B cell functioning." While exploring blunting the capacity of antigen engagement to induce B cell activation, Rossi and colleagues were able to show evidence of trogocytosis in lupus patients (2) . Trogocytosis is a mechanism of intercellular communication where two different types of cells form an "immunologic synapse" due to the interaction of receptors and ligands on acceptor and donor cells. Ligands and portions of the associated cell membrane are taken up and subsequently internalized by the acceptor cell. Trogocytosis can stimulate or suppress the immune response and is often mediated by any Fcc receptor type on various effector/acceptor cells.
In lupus patients, epratuzumab induces trogocytosis with the immunologic synapse being at the monocyte-B cell level. This results in effector cells using Fcc receptors to remove IgG-chelated antigens from donor cells. The donor is a B lymphocyte, and the acceptors are peripheral blood mononuclear cells and macrophages. The relevance and importance of this finding are not clear. Trogocytosis is also induced by rituximab, but with different targets. Recently published work has suggested that a novel epitope from CD22 regulates Th1 and Th17 cell function in SLE. Epratuzumab modulates human B cell maturation and cytokine production in response to Toll-like receptor 7, and does so without affecting B cell functioning (3-5).
Drugs for SLE: A 65-year quest and the epratuzumab experience
After hydroxychloroquine, prednisone, and aspirin were sanctioned for use in SLE by 1957, it was not until 2011 that belimumab received Food and Drug Administration (FDA) approval. Since 2000, 20 drugs have failed to achieve their primary end point in phase II and III clinical trials. This included several agents, such as rituximab and mycophenolate, that nearly all rheumatologists agree are effective. Several factors account for this failure: an ineffective or unsafe drug, flawed trial design, poor choice of a primary outcome measure, poor implementation of the trial, poor choice of concomitant medications, an artificial mandated use of steroids and tapering, and inadequate domains of SLE assessment.
Nearly all primary outcome measures involve the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (6) or British Isles Lupus Assessment Group (BILAG) index (7), which were devised between 1988 and 1992 and never intended for use in clinical trials and have serious deficiencies (8) . In the last 2 years, the Lupus Research Alliance, in collaboration with other lupus advocacy organizations and Outcome Measures in Rheumatology, has been able to gain access to data from pharmaceutical companies from their large phase III trial clinical report forms and assemble a response index that is similar in intent to the American College of Rheumatology criteria for 20% improvement (ACR20)/ ACR50/ACR70 for rheumatoid arthritis (9) . Within a few years, the SLEDAI and BILAG will become obsolete, and an index that includes reduction in inflammation, patient-reported outcomes, hospitalizations, organ damage, and mortality will be incorporated as part of this initiative (10) .
In the early 2000s, the original sponsor of epratuzumab conducted studies in lupus and SS before licensing the marketing rights for this agent in lupus in 2006, which led to an interruption of epratuzumab clinical trials. The ALLEVIATE trial enrolled 90 patients before being halted, and patients who had received 12 weeks of treatment had a 44% BILAG response rate (going from A to B or from B to C or D) versus 30% for placebo. Twentynine patients in the trial in the US were enrolled in an open-label extension where improvement in quality of life and corticosteroid dose reduction was noted (Clinical Trials.gov identifiers: NCT0011306 and NCT00383214). As with all epratuzumab trials, there were no safety issues (11, 12) . Under new sponsorship, a phase IIb study was initiated. EMBLEM (ClinicalTrials.gov identifier: NCT 00624351) was a short-duration, multicenter, randomized, double-blind, placebo-controlled, 12-week study that evaluated 5 dosing regimens. Patients had to be receiving prednisone (mean 14 mg a day) and were clearly quite ill (mean SLEDAI score of 14.8). B cell depletion ranged from 14-40% in treatment groups, but among the 227 study patients in the group receiving 600 mg weekly there was a dramatic BILAG-based Combined Lupus Assessment (BICLA) response rate (62% versus 30% for placebo; P = 0.03) (13) . This represented the first use of the BICLA, which is a BILAG-based composite measure. Remarkably, 38% of the patients receiving 600 mg had an "enhanced BILAG" improvement, meaning that A or B levels decreased by at least 2 letters (13) .
A wave of enthusiasm led to the initiation of two identical studies known as EMBODY (ClinicalTrials.gov identifier: NCT01262365), which was a 48-week phase III trial. At entry, patients were randomized to 1 of 2 dosing regimens or placebo and had to have 1 BILAG A or 2 BILAG B manifestations and a SLEDAI score of at least 6. The primary outcome measure was based on the BICLA composite end point. None of the primary or secondary end points were met among the 1,584 participants (14) . What happened? Clearly, lupus clinical design metrics need improvement. Further, the mean SLEDAI scores were 4 points less in the EMBODY study than in the EMBLEM study (indicating milder disease?), the quest for international and geographic diversity produced challenges, the results approached significance at 24 weeks (but not at the 48-week end point), and an unprecedented option for study centers to give patients real drug if they were nonresponders at 16 weeks may have biased investigators. Also, an unusually rapid improved response in the placebo group made little sense. As another example of the weakness of lupus trial outcomes design, 2 large identical phase III trials with an anti-BLyS/APRIL agent, tabalumab, had opposing results, with 1 of the 2 treated groups given the same drug and dose having statistically significant results.
Drug development for SS and epratuzumab
The only two systemic therapies approved by the FDA for SS are pilocarpine and cevimeline. Granted approval on the basis of single multicenter, randomized, placebo-controlled trials published in 1999 and 2002, systemic manifestations were not assessed. These agents clearly improved dry mouth, as indicated by symptoms, salivary flow, and use of artificial saliva. Cyclosporin ophthalmic emulsion and lifitegrast ophthalmic solution are approved for dry eye, which could be interpreted as including SS (for which they are widely used), even though it is not specifically mentioned in package inserts. An open-label, phase I/II study of epratuzumab in 16 patients with SS was completed in 2006 (15) . Participants received 4 doses 2 weeks apart and were followed up for 6 months. Fifty-three percent achieved a clinical response with statistically significant improvements in fatigue and patient's and physician's global assessments.
In light of these promising findings, in this issue of Arthritis & Rheumatology, Gottenberg et al explored whether epratuzumab had any impact on lupus patients 634 WALLACE who also had SS (16) . After obtaining cooperation from epratuzumab's two sponsors, it was found that 113 of 1,584 patients in the EMBODY trial who were anti-SSA positive also had SS symptoms. Remarkably, this subgroup achieved a significant BICLA response, reduction from baseline in BILAG total score, decreases in IgM, and B cell reduction. Physician's global assessment, anti-SSA levels, and SLEDAI scores clearly improved but did not achieve statistical significance. This improvement was noted in spite of the fact that 90% of this subset were taking corticosteroids and 30% were taking immunosuppressives at study entry. Those with an elevated C-reactive protein level had the best response. What lessons are learned from this analysis? It appears that those with the greatest amount of inflammatory activity respond best to epratuzumab. Alternatively, Gottenberg et al point out that since exocrine glands are the primary target for SS, epratuzumab may have a preferential effect upon antigendriven, germinal center-type B cell response. In any case, what should be the next steps to further explore this important post hoc observation?
Why have SS biologic trials failed? Controlled trials in SS are all less than 10 years old. The first hurdle to overcome was defining primary SS. In 2016, an ACR/European League Against Rheumatism (EULAR) group published criteria which now supersede the previous 4 sets of criteria published since 1990 (17) . The bottom line is simple but can be invasive. If a patient has anti-SSA, they need only to demonstrate objective evidence of dry eyes and dry mouth. If the patient is negative for anti-SSA, the only way to fulfill the criteria is to have a labial salivary gland biopsy. Hence, the prevalence of primary SS will be grossly underestimated and inclusion into clinical studies will be restricted unless an earlier classification criteria set is used.
The next hurdle involved developing an SS response index. Derived as part of a EULAR initiative, 39 SS experts (none of the authors and only 3 of the experts were from North America) identified 12 organ-specific domains extracted from 96 patients and 702 vignettes. From this, the EULAR Sj€ ogren's Syndrome Disease Activity Index (ESS-DAI) and EULAR Sj€ ogren's Syndrome Patient Reported Index (ESSPRI) were formulated (18, 19) . Since their publication in 2010, pharmaceutical companies have required an ESSDAI for trial participation and used ESSDAI as a primary or secondary outcome measure. Using these measures, neither hydroxychloroquine, baminercept, nor rituximab in two controlled trials showed any benefit. According to Fox and Fox (20) , the reason for slow enrollment and lack of response is related to several factors: 1) 90% of patients with primary SS have "benign glandular manifestations" (dry eyes or mouth, arthralgia, myalgia, fatigue, and vague cognitive changes) versus 10% who have extraglandular manifestations (vasculitis, lymphoma, cytopenias, and interstitial lung changes), 2) an ESSDAI of 6 requirement applies only to the 10% of the primary SS population with extraglandular manifestations, and 3) the two subsets should be studied separately. Other problems include the lack of correlation between ESSDAI and ESSPRI results, and that 7 of the 12 ESSDAI organ domains are affected in <5% of all patients with primary SS.
The EULAR working group deserves credit for addressing an important issue for the first time. The next step should be an analysis of clinical report forms from the completed trials from which an ACR20/50/70 for extraglandular and primarily glandular manifestations can be derived with an international collaboration of experts and SS advocacy organizations. SS is an inflammatory process, and acute-phase reactants and measures of inflammation make up only a small weighted proportion of current indices. For example, cytopenias, low complement levels, and acute-phase reactants account for only 18 of 123 possible points (14%) in the ESSDAI. According to ClinicalTrials.gov, there were at least 10 phase II or III trials for primary SS in the design phase, underway, or completed as of January 2018 that could be improved with a collaborative effort.
It is highly probable that an epratuzumab trial would fail if the ESSDAI and 2016 classification criteria for SS were used as primary outcome and inclusion criteria. Additional studies should be conducted to further explore epratuzumab's immunomodulating effects in SS and lupus.
Conclusion
There are~4 million people in the US with SLE or related conditions and various forms of SS. This group has ongoing inflammation, altered quality of life, as well as increased morbidity and mortality. The development of methods used to assess improvement in disease activity is far behind our ability to examine if promising agents such as epratuzumab are effective for these disorders.
